Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Athlete’s Foot Drug Labeling Changes Supported By NDAC Panel, Industry

This article was originally published in The Tan Sheet

Executive Summary

Current labeling for OTC drugs for Tinea pedis (athlete's foot) may mislead consumers toward greater expectations of benefit and should be changed, FDA's Nonprescription Drugs and Dermatologic and Ophthalmic Drugs advisory committees agreed unanimously at a May 6 meeting in Rockville, Md

You may also be interested in...



NDAC’s busy schedule

A two-day joint meeting of the Nonprescription and Dermatologic & Ophthalmic Drugs Advisory Committees is scheduled for March 24-25. The two committees discussed labeling issues for OTC athlete's foot drugs during a meeting in May (1"The Tan Sheet," May 10, 2004, p. 10). NDAC also is scheduled to meet with the Endocrinologic & Metabolic Drugs Advisory Committee Jan. 13-14...

NDAC’s busy schedule

A two-day joint meeting of the Nonprescription and Dermatologic & Ophthalmic Drugs Advisory Committees is scheduled for March 24-25. The two committees discussed labeling issues for OTC athlete's foot drugs during a meeting in May (1"The Tan Sheet," May 10, 2004, p. 10). NDAC also is scheduled to meet with the Endocrinologic & Metabolic Drugs Advisory Committee Jan. 13-14...

NDAC’s busy schedule

A two-day joint meeting of the Nonprescription and Dermatologic & Ophthalmic Drugs Advisory Committees is scheduled for March 24-25. The two committees discussed labeling issues for OTC athlete's foot drugs during a meeting in May (1"The Tan Sheet," May 10, 2004, p. 10). NDAC also is scheduled to meet with the Endocrinologic & Metabolic Drugs Advisory Committee Jan. 13-14...

Topics

UsernamePublicRestriction

Register

PS096809

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel